Table 7.
Hypomethylating therapy of MDS and AML real life studies
| References | Therapy | Patients (n) | Responses (%) | Responses time median (range) | Median OS (months) | Median PFS (months) |
| MDS | ||||||
| Fenaux, 2009 (42) | Azacitidine 75 mg/m2/7days | 179 pts | 17% CR/12% PR/10% HI | 2 cycles (1-16) | 24,5 | 17,8 |
| Voso, 2013 (40) | 196 pts | 19% CR/17% PR/21% HI | 4,5 cycles (7-15) | 17,1 | - | |
| Sebert, 2017 (53) | 702 pts MDS/AML | 44% ORR/15% CR | - | 14,9 | - | |
| AML | ||||||
| Dombret, 2015 (46) | Azacitidine 75 mg/m2/7days | 236 pz | 28% CR/CRi | - | 10,4 12,1* |
9,3 |
| Pleyer, 2017 (58) | 193 pz | 19% CR/CRi/PR | - | 10,7 | 13,8 | |
| Kantarjian, 2012 (49) | Decitabine 20 mg/m2/5days | 242 pz | 18% CR/CRp | 4,3 months | 7,7 | 8,5 |
| Blum, 2010 (50) | Decitabine 20 mg/m2/10days | 53 pz | 64% CR/CRi | 3 cycles (1-6) | 14 | 12 |
* Post-hoc analysis: time to the next treatment
CR = complete remission; CRi = CR with complete haematological recovery; PR = partial remission; HI = haematological improve¬ment; OS = overall survival; PFS: progression-free survival